Mifepristone More Effective Than Levonorgestrel and Yuzpe Method for Emergency Contraception but Increases Delayed Menstruation Risk
Mifepristone results in fewer pregnancies than levonorgestrel or the Yuzpe method when used for emergency contraception, according to evidence current to February 2025. While it effectively prevents pregnancy after unprotected sex, it also increases the risk of a delayed next menstrual period.
Key Clinical Takeaways:
- Mifepristone reduces pregnancy rates compared to standard levonorgestrel pills.
- Higher doses of mifepristone raise the likelihood of a late menstrual period.
- Current safety data on emergency contraception draw from 87 studies involving approximately 36,000 women.
How effective is mifepristone compared to standard emergency pills?
Emergency contraception prevents pregnancy after unprotected intercourse, birth control failures like a broken condom, or sexual assault. Common pill methods include levonorgestrel, marketed as Plan B One-Step, and the Yuzpe method, which combines multiple daily birth control pills. Mifepristone functions by blocking progesterone, a hormone required to maintain pregnancy.
Compared to levonorgestrel, a medium dose of mifepristone ranging from 25 mg to 50 mg results in fewer pregnancies, according to data compiled by Cochrane. If 35 out of 1,000 women given levonorgestrel become pregnant, about 23 out of 1,000 women do so when using mifepristone.
| Contraceptive Method | Pregnancies per 1,000 Women | Primary Side Effect Risk |
|---|---|---|
| Levonorgestrel (Standard) | 35 (baseline comparison) | Standard baseline risk |
| Medium-Dose Mifepristone (25-50 mg) | 23 | Increased late period risk |
| Low-Dose Mifepristone (<25 mg) | 15 | Reduced unwanted side effects |
| Yuzpe Method | 25 | Higher overall side effect risk |
Low doses of mifepristone under 25 mg also reduce pregnancies compared to levonorgestrel, dropping the rate from 20 per 1,000 down to 15 per 1,000 women. Against the Yuzpe method, any dose of mifepristone drops expected pregnancies from 25 per 1,000 down to 3 per 1,000 women.
What are the unwanted effects and menstrual changes?
The primary unwanted effect associated with mifepristone is a delay in a woman’s next menstrual period. This disruption occurs more frequently with higher doses.
Medium doses of mifepristone increase the risk of a late period compared to levonorgestrel. Low doses of mifepristone under 25 mg slightly increase this same risk of a late period while substantially reducing overall unwanted effects such as nausea and vomiting when compared to levonorgestrel.
When evaluated against copper intrauterine devices, researchers remain uncertain about the comparative effects of mifepristone on pregnancy rates, side effects, and menstrual timing due to limited direct study data.
What evidence supports these findings?
The findings draw from 87 studies encompassing around 36,000 women, primarily conducted in China between 1992 and 2015. The smallest study evaluated 16 participants, while the largest included 4,000 individuals.
Nearly half of the trials compared different doses of mifepristone, whereas 41 studies directly contrasted mifepristone with levonorgestrel. Five studies examined mifepristone against the Yuzpe method or intrauterine devices.
Limitations include a lack of clear methodological reporting in several older studies and a concentration of data from a single geographic region, meaning results may differ globally. Researchers found no direct studies comparing mifepristone to ulipristal acetate, commonly known by the brand name Ella.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.